drugset
Drugs / NVSI-06-08
last change Feb 2024 re-read 9 days ago

NVSI-06-08

also known as Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08)

Vaccine

Developed for
COVID-19 · pneumonia
Investigated by
Beijing Institute of Biological Products Co Ltd. · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China · China National Biotec Group Company Limited

Trials 2

today NCT05408312 · Ph 1 NCT05069129 · Ph 1/2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05408312 Jun 2022 → Feb 2024 pneumonia National Vaccine and Serum Institute, China Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05069129 Oct 2021 → Dec 2023 COVID-19 National Vaccine and Serum Institute, China Unknown No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2022-04-03 China National Biotec Group Company Limited Regulatory 重大进展！中国生物二代重组蛋白新冠疫苗获批临床 cnbg.com.cn ↗
2022年4月3日，国药集团中国生物二代重组蛋白新冠疫苗获得国家药品监督管理局颁发的临床试验批准文件。

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as NVSI-06-08 “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05408312 ↗
1

NCT05069129 ↗
Known as Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) “Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05408312 ↗
Modality Vaccine “NVSI-06-08 is a potential broad-spectrum recombinant COVID-19 vaccine” PMID 35760812 ↗ Jun 2022
Route Intramuscular “Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08) in the deltoid muscle of the upper arm” NCT05069129 ↗